News Release Detail
April 18, 2006
Mylan Announces Tentative Approval for Finasteride Tablets USP, 5mg
Mylan Announces Tentative Approval for Finasteride Tablets USP, 5mg
Mylan Announces Tentative Approval for Finasteride Tablets USP, 5mgPITTSBURGH, April 18 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration has
granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Application (ANDA) for Finasteride Tablets USP, 5mg. Finasteride Tablets
are the AB-rated generic equivalent of Merck's Proscar® Tablets, 5 mg, which
had annual U.S. sales of approximately $390 million as of December 31, 2005,
according to IMS Health.
About Mylan Laboratories
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com.
SOURCE Mylan Laboratories Inc.
04/18/2006
CONTACT: Media, Patrick Fitzgerald., or Investors, Kris King, of Mylan
Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)